MINAPHARM Pharmaceuticals (MIPH) Stock Overview
Produces medicines, chemicals, medical and dental supplies, cosmetics, veterinary and herbal medicines, and dietary supplements in Egypt and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
MIPH Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
MINAPHARM Pharmaceuticals Competitors
EI- Nile for Pharmaceuticals and Chemical Industries
GlaxoSmithKlineE
Alexandria For Pharmaceuticals & Chemical Industries
Kahira Pharmaceuticals & Chemical Industries
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ج.م700.00 |
| 52 Week High | ج.م772.00 |
| 52 Week Low | ج.م214.70 |
| Beta | 0.37 |
| 1 Month Change | 4.57% |
| 3 Month Change | 47.46% |
| 1 Year Change | 200.61% |
| 3 Year Change | 218.20% |
| 5 Year Change | 607.71% |
| Change since IPO | 7,600.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| MIPH | EG Pharmaceuticals | EG Market | |
|---|---|---|---|
| 7D | 7.4% | 5.7% | 3.1% |
| 1Y | 200.6% | 118.1% | 48.4% |
Return vs Industry: MIPH exceeded the EG Pharmaceuticals industry which returned 118.1% over the past year.
Return vs Market: MIPH exceeded the EG Market which returned 48.4% over the past year.
Price Volatility
| MIPH volatility | |
|---|---|
| MIPH Average Weekly Movement | 8.4% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in EG Market | 8.7% |
| 10% least volatile stocks in EG Market | 3.4% |
Stable Share Price: MIPH's share price has been volatile over the past 3 months compared to the EG market.
Volatility Over Time: MIPH's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of EG stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | n/a | Wafik El Bardissi | www.minapharm.com |
MINAPHARM Pharmaceuticals produces medicines, chemicals, medical and dental supplies, cosmetics, veterinary and herbal medicines, and dietary supplements in Egypt and internationally. It operates through Biological Production, Drug Production, and Other Pharmaceuticals segments. The company provides its products for the treatment of acne, alopecia, analgesics and anti-inflammation, atopic dermatitis, autoimmune disease, bone health, cardiovascular, cerebral insufficiency, diabetic neuropathy and retinopathy, dyslipidemia, gastroenterology and hepatology, glaucoma, hematoma and thrombosis, hemorrhoids, haemostasis, immuno-stimulants and immunomodulatory, and infertility, as well as for iron deficiency anemia, labour induction, menopause, nausea and vomiting, ocular infection and inflammation, osteoporosis, post operative management, pregnancy and lacation, probiotic and gut health, psoriasis, respiratory tract infection, rheumatoid arthritis, supplements, topical antibiotics, topical muscle relaxant, and venous disease.
MINAPHARM Pharmaceuticals Fundamentals Summary
| MIPH fundamental statistics | |
|---|---|
| Market cap | ج.م8.25b |
| Earnings (TTM) | ج.م6.62m |
| Revenue (TTM) | ج.م6.44b |
Is MIPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MIPH income statement (TTM) | |
|---|---|
| Revenue | ج.م6.44b |
| Cost of Revenue | ج.م4.14b |
| Gross Profit | ج.م2.30b |
| Other Expenses | ج.م2.29b |
| Earnings | ج.م6.62m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.56 |
| Gross Margin | 35.73% |
| Net Profit Margin | 0.10% |
| Debt/Equity Ratio | 66.5% |
How did MIPH perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 22:52 |
| End of Day Share Price | 2026/07/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MINAPHARM Pharmaceuticals is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.